Scott Wolchko | President & Chief Executive Officer |
Dan Shoemaker | Chief Scientific Officer |
Bob Valamehr | Chief Development Officer |
Wayne Chu | Senior Vice President, Clinical Development |
Robyn Karnauskas | Truist Securities |
Kelsey Goodwin | Guggenheim Securities |
Daina Graybosch | SVB Leerink |
Mara Goldstein | Mizuho |
Peter Lawson | Barclays |
Matt Biegler | Oppenheimer |
Aaron Welch | H.C. Wainwright |
Yigal Nochomovitz | Citigroup |
Biren Amin | Jefferies |
Jim Birchenough | Wells Fargo |
Alethia Young | Cantor Fitzgerald |
Welcome to Fate Therapeutics Second Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate's website at fatetherapeutics.com.
As a reminder, today's call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.